| Autor: |
Peters MN; Department of Internal Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana., Press CD, Moscona JC, Syed RH, Katz MJ, Egan AA, Bisharat MB, Nijjar VS, Anwar AH |
| Jazyk: |
angličtina |
| Zdroj: |
Proceedings (Baylor University. Medical Center) [Proc (Bayl Univ Med Cent)] 2012 Oct; Vol. 25 (4), pp. 346-8. |
| DOI: |
10.1080/08998280.2012.11928873 |
| Abstrakt: |
Glycoprotein (GP) IIb/IIIa receptor antagonists are powerful antiplatelet agents that are typically used in percutaneous coronary intervention. All three GP IIb/IIIa agents currently approved for use in the United States cause thrombocytopenia as a rare side effect. Abciximab is unique to the class in that it is a modified monoclonal antibody to the GP IIb/IIIa receptor, a property that can lead to increased platelet destruction. Presented herein is a patient who received a local infusion of abciximab for a lower-extremity thrombus and within 2 hours developed an acute profound thrombocytopenia that likely caused a large retroperitoneal hematoma. This case demonstrates the importance of checking platelet count within 2 to 4 hours after local (in addition to systemic) abciximab administration. Additionally, this report outlines how other causes of acute precipitous platelet drops, such as heparin-induced thrombocytopenia and pseudothrombocytopenia, can be rapidly excluded and allow for the prompt initiation of optimal therapy to minimize bleeding. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
